Long-term changes in serum IGF-1 levels after successful surgical treatment of growth hormone-secreting pituitary adenoma

Neurosurgery

Volumn 73, Issue 3, 2013, Pages 473-479

  Shin, Mi Seon ^a   Yu, Ji Hee ^a   Choi, Jong Han ^a   Jung, Chang Hee ^a   Hwang, Jenie Yoonoo ^a   Cho, Young Hyun ^b   Kim, Chang Jin ^b   Kim, Min Seon ^a  

^a Division of Endocrinology and Metabolism   (United States)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Acromegaly; Growth hormone; Insulin like growth factor 1; Pituitary tumor; Surgery

Indexed keywords

RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; FEMALE; HUMAN; HYPOPHYSIS ADENOMA; LONG TERM CARE; MALE; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OPERATION DURATION; ORAL GLUCOSE TOLERANCE TEST; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY;

ADENOMA; ADULT; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883297398     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.neu.0000431480.87160.84     Document Type: Article

References (20)

1. Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141-3148.
2. Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J. Harrison's Principle of Internal Medicine. 18th ed. New York, NY: McGraw-Hill Professional; 2011.
3. Espinosa-de-los-Monteros AL, Mercado M, Sosa E, et al. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly. J Neurosurg. 2002;97(2): 287-292. (Pubitemid 34827327)
4. Feelders RA, Bidlingmaier M, Strasburger CJ, et al. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J Clin Endocrinol Metab. 2005;90 (12):6480-6489. (Pubitemid 41759303)
5. Kreutzer J, Vance ML, Lopes MB, Laws ER Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab. 2001;86(9):4072-4077. (Pubitemid 32848515)
6. Lim EM, Pullan PT. Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society. J Clin Endocrinol Metab. 2004;89(7):3099-3102.
7. Takahashi JA, Shimatsu A, Nakao K,Hashimoto N. Early postoperative indicators of late outcome in acromegalic patients. Clin Endocrinol (Oxf). 2004;60(3):366-374. (Pubitemid 38297128)
8. Espinosa-de-Los-Monteros AL, Sosa E, Cheng S, et al. Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status. Clin Endocrinol (Oxf). 2006;64 (3):245-249.
9. Choi HK, Kong MH, Ahn BH, Kim SM, Lee DJ, Kim KM. Insulin-like growth factor 1 level and its relating factor in Korean healthy adults. Korean J Fam Med. 2009;30(1):15-22.
10. Shimatsu A, Fujieda K, Hanyu K, et al. Clinical evaluation of serum IGF-1, IGF-II, and IGFBP-3 measured by IRMA kits in adult blood. Horumon to Rinsho. 1996;44:1129-1238.
11. Friedrich N, Alte D, Völzke H, et al. Reference ranges of serum IGF-1 and IGFBP-3 levels in a general adult population: results of the Study of Health in Pomerania (SHIP). Growth Horm IGF Res. 2008;18(3):228-237. (Pubitemid 351479927)
12. Freda PU. Current concepts in the biochemical assessment of the patient with acromegaly. Growth Horm IGF Res. 2003;13(4):171-184. (Pubitemid 36980706)
13. Freda PU. Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin Endocrinol (Oxf). 2009;71(2):166-170.
14. Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab. 1998;83(11):3808-3816. (Pubitemid 28513555)
15. Serri O, Beauregard C, Hardy J. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab. 2004;89(2):658-661. (Pubitemid 38269873)
16. Alexopoulou O, Bex M, Abs R, T'Sjoen G, Velkeniers B, Maiter D. Divergence between growth hormone and insulin-like growth factor-1 concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab. 2008;93(4):1324-1330. (Pubitemid 351519728)
17. Carmichael JD, Bonert VS, Mirocha JM, Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab. 2009;94(2):523-527.
18. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94(5):1509-1517.
19. Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf). 2007;67(1):65-70. (Pubitemid 46955441)
20. Granada ML, Ulied A, Casanueva FF, et al. Serum IGF-I measured by four different immunoassays in patients with adult GH deficiency or acromegaly and in a control population. Clin Endocrinol (Oxf). 2008;68(6):942-950. (Pubitemid 351703937)